ara-290
TISSUE PROTECTION · EPO MIMETIC · 11 AA
also: cibinetide · ARA290 · pHBSP
ARA-290 is an 11-residue peptide engineered from the helix B surface of erythropoietin to activate the innate repair receptor without erythropoietic activity. Randomised phase 2 trials in sarcoidosis-associated small fibre neuropathy and type 2 diabetes reported improvements in symptoms and in objectively measured corneal nerve fibre metrics, but no phase 3 trial has been conducted.
// our evidence grade — unedited
It has the cleanest development record of the non-approved compounds here - registered phase 2 and 2b randomised trials with objective histological endpoints and an FDA orphan designation - but it never reached phase 3 and development appears to have stalled.
We grade this compound and we sell it. The grade is set against our published criteria before any stocking decision and is not adjusted because it is in the catalogue.
read the full evidence →// specification
| full name | Cibinetide, an 11-amino-acid erythropoietin helix-B surface peptide |
| cas | 1208243-50-8 |
| formula | C51H84N16O21 |
| molar mass | 1257.32 g/mol |
| purity | ≥ 99% HPLC |
| form | lyophilised powder, sealed vial |
| storage | Lyophilised powder is typically stored at -20 °C protected from light; reconstituted laboratory solutions are refrigerated at 2-8 °C for short-term use or aliquoted and frozen to avoid repeated freeze-thaw. |
| solubility | Water-soluble; reconstituted in sterile water, saline or aqueous buffer for laboratory work. |
| sequence | QEQLERALNSS |
// select size
crypto payment · research use only · not for human consumption
// others in Healing & Repair